TOI Hits New High - Revenue Projected To Grow 17% To 22% In 2025, Profitable By 2026

Shares of The Oncology Institute Inc. (TOI) touched a new 52-week high of $3.76 yesterday, driven by renewed investor confidence and growing market enthusiasm surrounding the company's performance and outlook.

This U.S.-based, community-focused oncology care provider operates 67 clinics across California, Florida, Arizona, Oregon, and Nevada. It offers comprehensive cancer treatment services, including chemotherapy, immunotherapy, oncolytics, and radiation oncology. TOI supports patients through coordinated case management, drug formulary oversight, and fully delegated networks of care providers. It also operates a specialty pharmacy that dispenses oral and self-injectable medications both in-office and by mail. Beyond patient care, TOI plays an active role in advancing clinical research in oncology, hematology, and supportive therapies and devices.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com